12:00 AM
 | 
Jul 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Perifosine: Interim Phase I data

Interim data from 24 patients in an open-label, dose-escalation, U.S. Phase I trial showed that perifosine produced a 12-month progression-free survival (PFS) rate of 50%, including 1 complete remission based on iodine-131-meta-iodobenzylguanidine (MIBG) scan. Additionally, 3 patients had improved MIBG scan and normalized bone marrow histology at >37 months follow-up. Perifosine was well tolerated with no grade 3 adverse events. The trial is scheduled to enroll 36 patients with chemo-...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >